×
Clene Net Profit Margin 2018-2024 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Clene net profit margin from 2018 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Clene Net Profit Margin 2018-2024 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Clene net profit margin from 2018 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$147B
Gilead Sciences (GILD)
$116B
Bristol Myers Squibb (BMY)
$115.8B
Vertex Pharmaceuticals (VRTX)
$110.2B
CSL (CSLLY)
$81.9B
Regeneron Pharmaceuticals (REGN)
$74.7B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$38.6B
Alnylam Pharmaceuticals (ALNY)
$34.4B
BioNTech SE (BNTX)
$27.6B
Illumina (ILMN)
$22.3B
BeiGene (ONC)
$21.7B
Biogen (BIIB)
$20.8B
Moderna (MRNA)
$14.8B
Insmed (INSM)
$14B
Incyte (INCY)
$13.9B
Genmab (GMAB)
$13.9B
Genmab (GNMSF)
$13.9B
Intra-Cellular Therapies (ITCI)
$13.5B
Bio-Techne Corp (TECH)
$12.5B
BioMarin Pharmaceutical (BMRN)
$11.8B
Sarepta Therapeutics (SRPT)
$11.1B
Vaxcyte (PCVX)
$10.8B
QIAGEN (QGEN)
$10.8B
Exact Sciences (EXAS)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.8B
Exelixis (EXEL)
$9.4B
Repligen (RGEN)
$9.3B
Roivant Sciences (ROIV)
$8.1B